{"date":"2026-04-04","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-3176-2026-04-04-1956-290uoc","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2026-04-04","time":"19:56:14","subject":"開發中新藥OBP-301通過日本適合性書面審查及GCP實地查核","clause":"第53款","fact_date":"2026-04-03","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2026-04-04 19:56，「開發中新藥OBP-301通過日本適合性書面審查及GCP實地查核」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2026-04-04-1103-of9dge","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2026-04-04","time":"11:03:37","subject":"本公司公告難治型憂鬱症新劑型新藥ALA-3000美國臨床一期試驗結果","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2026-04-04 11:03，「本公司公告難治型憂鬱症新劑型新藥ALA-3000美國臨床一期試驗結果」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}